Sanofi

Sanofi, Regeneron collaborate on immuno-oncology

Wednesday, July 29, 2015

Sanofi and Regeneron Pharmaceuticals have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology. The two companies will jointly develop a programmed cell death protein 1 (PD-1) inhibitor currently in phase I testing, and plan to initiate clinical trials in 2016 with new therapeutic candidates based on ongoing, innovative preclinical programs.

[Read More]

FDA approves Sanofi, Regeneron’s Praluent (alirocumab) Injection

Monday, July 27, 2015

The FDA has approved Sanofi and Regeneron Pharmaceuticals’ Praluent (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Praluent is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein (LDL) cholesterol. The effect of Praluent on cardiovascular morbidity and mortality has not been determined.

[Read More]

Report: Innovation trends in treatments for rare diseases and widespread conditions

Wednesday, June 17, 2015

The antibiotics market is at risk of losing another decade to inadequate levels of research and innovation, according to international intellectual property firm Marks & Clerk’s new report From rare to routine—medicines for rare diseases, vaccines and antibiotics. Research highlights the striking difference between research levels into rare diseases, vaccines and antibiotics across the globe.

[Read More]

CPhI Pharma Awards 2015 open with five new categories

Monday, June 15, 2015

CPhI Worldwide, organized by UBM EMEAhas opened the annual CPhI Pharma Awards for 2015, with five new categories covering the entire pharmaceutical supply chain. Now in their 12th consecutive year, the awards will honor companies and individuals driving the pharma industry forward through innovations, new approaches, technologies and strategies.  

[Read More]

EMD Serono makes key oncology appointments

Thursday, May 28, 2015

EMD Serono, the U.S. biopharmaceutical business of Germany’s Merck, has announced two critical management appointments to lead its entry into oncology. EMD Serono’s diversified oncology and immuno-oncology pipeline includes multiple, high-priority projects currently in development to optimize patient outcomes in challenging cancers that have significant unmet patient need.

[Read More]